Cyxone advances the patent portfolio for Rabeximod
Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that national phase filings have been completed in a large number of relevant markets for four of its pending PCT applications directed to clinically applicable forms and formulations of Rabeximod, as well as their medical use, potentially conferring patent protection until 2041.
In November 2020 Cyxone reported the filing of five new patent applications though the international patent cooperation treaty (PCT) in order to strengthen the intellectual property protection for Rabeximod. Cyxone today reports the continued advancement of the five PCT applications according to plan, where 4 applications now have successfully converted to national phase. The patents of relevance are:
PCT/EP2021/065705: ORAL FORMULATION COMPRISING A CRYSTALLINE FORM OF RABEXIMOD
PCT/EP2021/065697: RABEXIMOD IN THE TREATMENT OF RHEUMATOID ARTHRITIS
PCT/EP2021/065693: NEW USE OF RABEXIMOD
PCT/EP2021/065694: METHOD FOR PREPARING A CRYSTALLINE FORM OF RABEXIMOD
”We are glad to announce that the patent process for our 5 new patent applications is advancing according to plan. The patent process may be difficult to navigate, which requires the assistance of skilled patent attorneys and dedicated specialists. Four of our five PCT applications have now been converted to national phase applications in relevant national markets. The national phase conversion is an important milestone in the patent journey, indicating that the patents have passed various stages of critical review. The patents if granted will confer patent protection until 2041.” comments Carl-Magnus Högerkorp, CEO, Cyxone
Contact
Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com